Universal Health Services, Inc.

LSE:0LJL Stock Report

Market Cap: US$12.7b

Universal Health Services Valuation

Is 0LJL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0LJL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$232.60
Fair Value
15.4% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: 0LJL ($196.83) is trading below our estimate of fair value ($232.6)

Significantly Below Fair Value: 0LJL is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0LJL?

Key metric: As 0LJL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0LJL. This is calculated by dividing 0LJL's market cap by their current earnings.
What is 0LJL's PE Ratio?
PE Ratio10.6x
EarningsUS$1.20b
Market CapUS$12.68b

Price to Earnings Ratio vs Peers

How does 0LJL's PE Ratio compare to its peers?

The above table shows the PE ratio for 0LJL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.2x
CVSG CVS Group
46.4x20.79%UK£899.6m
SPI Spire Healthcare Group
31.6x24.17%UK£799.1m
SN. Smith & Nephew
31.3x16.56%UK£9.5b
CTEC ConvaTec Group
39.4x16.92%UK£5.6b
0LJL Universal Health Services
10.6x5.32%US$12.7b

Price-To-Earnings vs Peers: 0LJL is good value based on its Price-To-Earnings Ratio (10.6x) compared to the peer average (37.2x).

Price to Earnings Ratio vs Industry

How does 0LJL's PE Ratio compare vs other companies in the European Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0LJL 10.6xIndustry Avg. 18.8xNo. of Companies6PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0LJL is good value based on its Price-To-Earnings Ratio (10.6x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0LJL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0LJL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.6x
Fair PE Ratio37.5x

Price-To-Earnings vs Fair Ratio: 0LJL is good value based on its Price-To-Earnings Ratio (10.6x) compared to the estimated Fair Price-To-Earnings Ratio (37.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0LJL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$196.83
US$223.90
+13.75%
10.24%US$280.00US$186.41n/a16
May ’26US$176.07
US$223.46
+26.92%
10.46%US$280.00US$186.41n/a16
Apr ’26US$186.83
US$228.65
+22.38%
11.02%US$280.00US$186.41n/a16
Mar ’26US$171.55
US$230.95
+34.62%
11.20%US$280.00US$176.21n/a15
Feb ’26US$189.35
US$233.68
+23.41%
12.11%US$274.00US$176.21n/a15
Jan ’26US$179.18
US$238.21
+32.95%
9.71%US$274.00US$197.00n/a15
Dec ’25US$205.00
US$240.81
+17.47%
8.33%US$274.00US$211.00n/a15
Nov ’25US$205.12
US$247.81
+20.81%
8.98%US$275.00US$211.00n/a15
Oct ’25US$223.55
US$240.20
+7.45%
7.12%US$274.00US$219.00n/a16
Sep ’25US$235.50
US$235.76
+0.11%
7.88%US$267.00US$189.00n/a16
Aug ’25US$213.16
US$230.27
+8.03%
8.73%US$256.00US$186.00n/a15
Jul ’25US$183.21
US$198.53
+8.36%
9.22%US$236.00US$156.00n/a15
Jun ’25US$187.34
US$194.20
+3.66%
7.55%US$226.00US$156.00n/a15
May ’25US$170.30
US$189.79
+11.44%
6.50%US$208.00US$156.00US$176.0714
Apr ’25US$182.57
US$188.00
+2.97%
6.87%US$208.00US$156.00US$186.8314
Mar ’25US$171.74
US$178.23
+3.78%
9.81%US$208.00US$144.00US$171.5513
Feb ’25US$163.61
US$162.38
-0.75%
8.54%US$190.00US$140.00US$189.3513
Jan ’25US$152.04
US$154.62
+1.70%
8.13%US$175.00US$140.00US$179.1813
Dec ’24US$138.32
US$150.15
+8.56%
6.46%US$170.00US$139.00US$205.0013
Nov ’24US$125.56
US$151.77
+20.88%
6.42%US$170.00US$140.00US$205.1213
Oct ’24US$125.91
US$155.86
+23.79%
6.39%US$172.00US$142.00US$223.5514
Sep ’24US$133.91
US$158.13
+18.09%
7.14%US$183.00US$142.00US$235.5015
Aug ’24US$139.14
US$157.33
+13.08%
7.68%US$183.00US$140.00US$213.1615
Jul ’24US$158.08
US$153.87
-2.67%
7.00%US$178.00US$139.00US$183.2115
Jun ’24US$132.57
US$152.87
+15.31%
5.91%US$170.00US$139.00US$187.3415
May ’24US$149.50
US$148.20
-0.87%
7.57%US$165.00US$124.00US$170.3015
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
US$223.91
Fair Value
12.1% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 14:39
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Universal Health Services, Inc. is covered by 40 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hua HaBaird
Adam FeinsteinBarclays
Andrew MokBarclays